respons oral leukoplakia beta-caroten leukoplakia increas risk oral cancer premalign lesion retinoid retino acid leukoplakia drug consider toxic suitabl large-scal use prevent oral cancer beta-caroten nontox carotenoid biolog properti efficaci oral leukoplakia random studi retino acid mg/kg/d beta-caroten mg/d leukoplakia mark differ toxic compound consent form initi elig patient beta-caroten studi design phase II trial beta-caroten compound month patient month treatment lesion entri respons bidimension measur photographi entri treatment studi complet twenty-four evalu patient major respons complet partial respons rate confid limit signific toxic drug discontinu dose reduct result beta-caroten substanti activ oral premalign lack toxic excel candid prevent agent oral cancer 